Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Donaldson Capital Management LLC

Donaldson Capital Management LLC trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 11.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 606,303 shares of the biopharmaceutical company's stock after selling 76,431 shares during the quarter. Donaldson Capital Management LLC's holdings in Bristol-Myers Squibb were worth $31,109,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Herold Advisors Inc. grew its position in Bristol-Myers Squibb by 3.2% during the 3rd quarter. Herold Advisors Inc. now owns 33,668 shares of the biopharmaceutical company's stock valued at $1,954,000 after purchasing an additional 1,051 shares during the last quarter. Kestra Private Wealth Services LLC lifted its stake in Bristol-Myers Squibb by 9.5% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 139,811 shares of the biopharmaceutical company's stock valued at $8,115,000 after acquiring an additional 12,121 shares during the period. Metis Global Partners LLC lifted its stake in Bristol-Myers Squibb by 14.8% during the 3rd quarter. Metis Global Partners LLC now owns 101,772 shares of the biopharmaceutical company's stock valued at $5,907,000 after acquiring an additional 13,122 shares during the period. Jmac Enterprises LLC lifted its stake in Bristol-Myers Squibb by 11.4% during the 3rd quarter. Jmac Enterprises LLC now owns 12,171 shares of the biopharmaceutical company's stock valued at $706,000 after acquiring an additional 1,245 shares during the period. Finally, Vontobel Holding Ltd. lifted its stake in Bristol-Myers Squibb by 17.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 3,653,151 shares of the biopharmaceutical company's stock valued at $212,029,000 after acquiring an additional 530,405 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Price Performance

Shares of BMY stock traded up $0.23 on Monday, reaching $48.51. The company's stock had a trading volume of 11,901,640 shares, compared to its average volume of 15,958,668. The stock's fifty day simple moving average is $51.29 and its 200-day simple moving average is $51.69. Bristol-Myers Squibb has a 1 year low of $47.58 and a 1 year high of $70.93. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $98.32 billion, a price-to-earnings ratio of 12.57, a price-to-earnings-growth ratio of 1.78 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts' consensus estimates of $1.55 by $0.15. The firm had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. Bristol-Myers Squibb's revenue for the quarter was up .6% compared to the same quarter last year. During the same period last year, the firm posted $1.82 earnings per share. Analysts forecast that Bristol-Myers Squibb will post 5.41 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 4.95%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb's payout ratio is 62.18%.

Analysts Set New Price Targets

Several research firms have issued reports on BMY. Wells Fargo & Company lowered their target price on shares of Bristol-Myers Squibb from $58.00 to $51.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 6th. William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. StockNews.com cut shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Monday. Bank of America cut shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Finally, Societe Generale cut shares of Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research note on Monday, March 11th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $61.12.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.